Cancer NetworkOriginal article
<![CDATA[Isatuximab Combo Increases MRD Negativity in MRD-Positive Multiple Myeloma]]>
Phase 3positiveIsatuximabPositive
AI Analysis
Summary
Phase 3 MIDAS trial shows isatuximab combination therapy increased MRD negativity in MRD-positive multiple myeloma patients. Longer follow-up is needed to assess impact on progression-free and overall survival.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Isatuximab combo increased MRD negativity in MRD-positive multiple myeloma patients
Importance:6/10
Sentiment:
0.60
multiple myelomaMRD negativityphase 3MIDAS trialoncology
Related Companies
Read the original article
Published by Cancer Network on September 25, 2026 3:00 PM